The partners will use Protagen’s autoantibody measuring technology to identify biomarkers of patient response to cancer immunotherapies.
The company said that it can distinguish patients suffering from lupus from those with other autoimmune diseases using its antibody array platform.
The company has partnered with the German National Center for Tumor Diseases to identify biomarkers for predicting response to immunotherapy in melanoma patients.
The license allows Inova to include the BICD2 biomarker in its portfolio of connective tissue disease reagents aimed at the diagnosis of systemic sclerosis.
The company now offers three CE-marked autoantibody assays — for BICD2, Scl70, and CENP-B — that can be used for clinical management of the condition.
According to the company, some of the autoantibodies it has identified as disease markers appear to be directed against potentially interesting drug targets.
Researchers from Protagen, Targos, and elsewhere have identified autoantibody biomarkers specific to patients diagnosed with prostate cancer.
The company hopes to identify a subset of predictive markers from a current panel of 100 proteins it identified as possibly useful through previous RA studies.
The companies are co-developing an assay that differentiates previously infected, seropositive Lyme disease patients from newly infected individuals.
The certification covers the development, production, and distribution of in vitro diagnostics for autoimmune disease.
In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.
The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.
Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.
In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.